Bergamot
Citrus bergamia polyphenol extract
Written by Aaron CuhaReviewed Sep 2026
Also known as: Citrus bergamia, Bergamot polyphenolic fraction, BPF
Fourteen randomised trials show large lipid changes, including LDL down 55 mg/dL. The effect sizes are implausibly large for a food extract, the trials are small and regionally concentrated, and no outcome trial exists.
Overview
Bergamot is a citrus fruit whose polyphenol extract has a randomised literature on blood lipids, and the honest reading of that literature is that it is both real and hard to believe.
A meta-analysis of 14 randomised trials found total cholesterol down 63.6 mg/dL, LDL down 55.4 mg/dL and triglycerides down 74.7 mg/dL. For context, those numbers are in the range of a moderate statin dose, produced by a fruit extract. The same review's authors say the results for nutraceutical compounds containing bergamot were inconsistent and that clinical efficacy needs establishing through higher-quality studies.
When effect sizes look like that, the two possibilities are a genuinely potent compound or a literature with problems. This page reports the numbers and the reasons for caution together, rather than picking one.
Mechanism of action
The bergamot polyphenolic fraction is rich in flavanones, notably brutieridin and melitidin, which carry a side chain structurally similar to the statin pharmacophore. That has led to the hypothesis of partial HMG-CoA reductase inhibition, which would make it a weak statin rather than a generic antioxidant. Other proposed actions include AMPK activation and pancreatic cholesterol ester hydrolase inhibition reducing cholesterol absorption. The statin-like mechanism remains a structural inference supported by preclinical work, not something demonstrated in humans.
Human evidence
A modest randomised literature with strikingly large reported effects on lipid panels, and no trial measuring a clinical event.
- 14 randomised trials pooled: LDL down roughly 55 mg/dL and triglycerides down roughly 75 mg/dL against control.
- The individual trials are small and heavily concentrated in one research community in Italy, where the plant is grown and the extract is produced.
- Every endpoint is a blood lipid. No trial has measured heart attacks, strokes or deaths.
- The reviewers themselves report that results across nutraceutical products containing bergamot were inconsistent, which points at product variability rather than a single reliable intervention.
What this does not tell you: Effect sizes of this magnitude from a food extract should raise the question of whether the literature is measuring what it appears to. Small single-region trials with large effects are the classic setup for a result that shrinks as better trials arrive, and that pattern has played out repeatedly in nutraceutical research. There is also no standardisation across products, so a positive trial of one extract is weak evidence about a different bottle. Lowering a lipid number is not the same as preventing an event, and no bergamot trial has attempted the second.
Reading the research record
Bergamot sits in the awkward zone this site exists to describe accurately. The randomised evidence is not absent, which is where most supplements sit, and it is not robust either. Publication and small-study effects would both push in the direction seen here, and the concentration of the literature in the region that produces the extract is a reason for care rather than an accusation. The fair statement is that a reader with a difficult lipid panel has a plausible, cheap, low-risk thing to try with a measurable marker attached, and no basis for believing it prevents cardiovascular events.
The evidence, charted
Fig. 1 · evidence composition
0of 1 citation (0%) is in people
Every citation cited here is Review work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2022.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Review2022
The effect of bergamot supplementation on lipid profiles: a systematic review and meta-analysis of randomized controlled trials
14 randomised trials. Total cholesterol minus 63.60 mg/dL (95% CI minus 78.03 to minus 49.18), triglycerides minus 74.72 mg/dL, LDL minus 55.43 mg/dL and HDL up 5.78 mg/dL, all p < 0.001. The authors state that results for nutraceutical compounds containing bergamot were inconsistent and that clinical efficacy needs establishing through higher-quality studies.
Phytotherapy Research
Frequently asked questions
Does bergamot really lower LDL by 55 points?
That is what the pooled meta-analysis of 14 randomised trials reports. It is also a large enough effect to warrant scepticism from a food extract, the trials are small and regionally concentrated, and the reviewers themselves call for higher-quality studies. Treat it as promising rather than established.
Is it a natural statin?
The interesting version of that claim is structural: two of its flavanones carry a side chain resembling the statin pharmacophore, which makes partial HMG-CoA reductase inhibition plausible. That has not been demonstrated in humans. Calling it a natural statin overstates what has been shown.
Does the product matter?
Probably a great deal. This is a standardised extract rather than a single molecule, products differ in flavanone content, and the meta-analysis found results inconsistent across nutraceutical products containing bergamot. If you try it, match the extract to one used in a trial.